Researchers at the Salk Institute have developed a method called Superb-seq that can identify both the intended and unintended edits CRISPR makes to DNA, and show which individual cells carry them. The study, published in Nature Methods, describes a tool that reads out all edits, on-target and off-target, along with the changes they cause in gene activity, at single-cell resolution.
The problem Superb-seq addresses has been well known for some time. CRISPR/Cas9 can cut DNA in places it was never meant to touch, and existing methods can show where those unwanted edits sit in the genome but not which cells carry them or how they affect cell behavior. Superb-seq combines Cas9 editing, a short edit-reporting DNA sequence, and single-cell RNA sequencing to link each edit to its effect on gene expression.
The team tested the method on 34,000 cells from three cell lines. In one group of 10,000 human leukemia cells grown in the lab, Superb-seq detected 43 edit sites, 36 of them off-target, across 5,761 edited cells. The researchers also reported that it picked up gene expression changes caused by edits that existing edit-detection methods could not see, and that it improved on the earlier Perturb-seq approach, which reads gene expression and guide RNAs but not the resulting edits.
Co-first author Brad Balderson noted that off-target edits could disrupt genes that protect against cancer, so knowing which cells are affected matters as much as knowing where the edits occur. Graham McVicker, who leads the lab, said the scale of the problem surprised him, since off-target edits were far more frequent than he had expected.
The authors see potential uses in basic research, drug development, personalized medicine, and training machine learning models. Because genomes differ between people, they suggest Superb-seq could help assess the off-target profile of an individual's genome before choosing a genome-editing therapy. The team has filed a patent on the method.